Per Byström - Concepedia

Concepedia

Author

Per Byström

Karolinska Institutet

Also Known As

P Byström, P. Bystrom, P. Byström, Per Byström, Per Byström

22

Publications

1.1K

Citations

13

H-Index

18

Concepts

All Affiliations

Karolinska Institutet Uppsala University Hospital Uppsala University Karolinska University Hospital Lund University

PB

About

Per Byström is an author at Karolinska Institutet specializing in oncology, colorectal cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	271
2	Health Sciences	2	2	92
3	Pathology	2	2	131
4	Pharmacology	1	1	48
5	Radiation Medicine	1	1	21

Per Byström

×

13

Publications

1.1K

Citations

13

H-Index

	Year	Citations
Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer Morten Brændengen, Kjell M. Tveit, Åke Berglund, Journal of Clinical Oncology	2008	478
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer Bengt Glimelius, Hans Garmo, Åke Berglund, The Pharmacogenomics Journal	2010	121
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy Lennart Blomqvist, Anders Sundin, Hans Jacobsson, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineTumor SizeColorectal Cancer	2011	106
TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid Nanna Møller Sørensen, Per Byström, Ib Jarle Christensen, Clinical Cancer Research	2007	77
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer Per Byström, Åke Berglund, Ulrike Garske, Annals of Oncology Positron Emission TomographyMedical ImagingMedicineMolecular ImagingColorectal Cancer	2009	71
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer Bengt Glimelius, Halfdan Sørbye, Lise Balteskard, Annals of Oncology OncologyFolinic Acid ScheduleGastrointestinal OncologyMedicineColorectal Cancer	2008	48
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib Aglaia Maleka, Gunnar Åström, Per Byström, BMC Cancer	2016	42
Evaluation of predictive markers for patients with advanced colorectal cancer Per Byström, Åke Berglund, Peter Nygren, Acta Oncologica	2012	38
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma Pehr Lind, Bengt Isaksson, Markus Almström, Acta Oncologica	2008	34
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer Bengt Glimelius, Michael Lahn, Sulochana R. Gawande, Annals of Oncology Surgical OncologyChemonaive PatientsGastrointestinal OncologyMedicinePathology	2009	25

Page 1